Novo Nordisk's China Obesity Drug Cuts Nearly One-Fifth Of Body Weight [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (NYSE: NVO ) on Tuesday shared topline results from a Chinese phase 2 trial of UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon (triple G). In March 2025, the companies inked an exclusive license agreement worth over $2 billion in upfront and milestone payments. United Biotechnology is responsible for the development of UBT251 in the Chinese mainland, Hong Kong, Macau, and Taiwan, while Novo Nordisk is responsible for the development in the rest of the world. Don't Miss: The ‘ChatGPT of Marketing' Just Opened a $0.85/Share Round — 10,000+ Investors Are Already In Explore the Fire-Safe Energy Storage Company With $185M in Contracted Revenue Positioning Against Eli Lilly's Retatrutide UBT251 is designed to challenge Eli Lilly & Co.'s (NYSE: LLY ) ‘Triple G' obesity drug, retatrutide, which has already shown promising weight loss results. The China trial, conducted by
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk Shares Sink 21% as Obesity Shot Trails Lilly Rival [Yahoo! Finance]Yahoo! Finance
- SA analyst upgrades/downgrades: NVDA, NKE, SMCI, NVO [Seeking Alpha]Seeking Alpha
- Clinical ink Appoints Dr. Christian Born Djurhuus, MD, PhD as Chief Science OfficerPR Web
- Novo Nordisk's Torrid Week Erases Last of Wegovy-Fueled Gains [Yahoo! Finance]Yahoo! Finance
- 12 Press Releases You Need to See This Week [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 2/23/26 - Form 6-K
- 2/23/26 - Form 6-K
- 2/20/26 - Form 6-K
- NVO's page on the SEC website